| Literature DB >> 30408753 |
Aneesh Chandrasekharan1, Shankara Narayanan Varadarajan1, Asha Lekshmi1, Santhik Subhasingh Lupitha1, Pramod Darvin1, Leena Chandrasekhar1, Prakash Rajappan Pillai1, T R Santhoshkumar2, M Radhakrishna Pillai1.
Abstract
Most toxic compounds including cancer drugs target mitochondria culminating in its permeabilization. Cancer drug-screening and toxicological testing of compounds require cost-effective and sensitive high-throughput methods to detect mitochondrial damage. Real-time methods for detection of mitochondrial damage are less toxic, allow kinetic measurements with good spatial resolution and are preferred over end-stage assays. Cancer cell lines stably expressing genetically encoded mitochondrial-targeted redox-GFP2 (mt-roGFP) were developed and validated for its suitability as a mitochondrial damage sensor. Diverse imaging platforms and flow-cytometry were utilized for ratiometric analysis of redox changes with known toxic and cancer drugs. Key events of cell death and mitochondrial damage were studied at single-cell level coupled with mt-roGFP. Cells stably expressing mt-roGFP and H2B-mCherry were developed for high-throughput screening (HTS) application. Most cancer drugs while inducing mitochondrial permeabilization trigger mitochondrial-oxidation that can be detected at single-cell level with mt-roGFP. The image-based assay using mt-roGFP outperformed other quantitative methods of apoptosis in ease of screening. Incorporation of H2B-mCherry ensures accurate and complete automated segmentation with excellent Z value. The results substantiate that most cancer drugs and known plant-derived antioxidants trigger cell-death through mitochondrial redox alterations with pronounced ratio change in the mt-roGFP probe. Real-time analysis of mitochondrial oxidation and mitochondrial permeabilization reveal a biphasic ratio change in dying cells, with an initial redox surge before mitochondrial permeabilization followed by a drastic increase in ratio after complete mitochondrial permeabilization. Overall, the results prove that mitochondrial oxidation is a reliable indicator of mitochondrial damage, which can be readily determined in live cells using mt-roGFP employing diverse imaging techniques. The assay described is highly sensitive, easy to adapt to HTS platforms and is a valuable resource for identifying cytotoxic agents that target mitochondria and also for dissecting cell signaling events relevant to redox biology.Entities:
Keywords: Apoptosis; Drug screening; Mitochondria; Mitochondrial oxidation; roGFP
Mesh:
Substances:
Year: 2018 PMID: 30408753 PMCID: PMC6222140 DOI: 10.1016/j.redox.2018.10.013
Source DB: PubMed Journal: Redox Biol ISSN: 2213-2317 Impact factor: 11.799
Fig. 1(A). U2OS cells were transfected with roGFP targeted at mitochondria as described. The bright field and respective EGFP channels are shown. The above panel shows heterogenous expression of roGFP. The below panel represents a single cell colony expanded after selection that shows the homogenous level of expression. The inset shows an enlarged part of the image. (B). U2OS cells stably expressing mt-roGFP were left untreated or treated with staurosporine (2 µM), camptothecin (30 µM), Menadione (20 µM) for 24 h. The cells were stained with MitoSOX Red to detect Mitochondrial ROS as described. Control cells showed no MitoSOX Red signal with an average ratio of 0.5 for roGFP. In treated cells, there is a significant increase in MitoSOX Red fluorescence concomitant with an increase in roGFP ratio. (C). U2OS cells stably expressing mt-roGFP and HyPer-red targeted at mitochondria were left untreated or treated with cisplatin (150 µM), camptothecin (30 µM) for 24 h. Control cells showed low HyPer-Red signal with an average ratio of 0.5 for roGFP. In treated cells, there is a significant increase in HyPer-Red fluorescence corresponding with an increase in roGFP ratio.
Fig. 2(A). U2OS cells stably expressing mt-roGFP were left untreated or treated with indicated drugs and natural compounds for 24 h. The cells were stained with TMRM to detect mitochondrial membrane potential as described. Control cells showed mitochondrial TMRM staining with an average ratio of 0.5 for roGFP. In treated cells, there is a significant drop in TMRM staining concomitant with an increase in the roGFP ratio. (B). U2OS cells stably expressing mt-roGFP were transiently transfected with IMS-RP plasmids. The cells were treated with cisplatin (150 µM), and CCCP (10 µM) for 24 h. Control cells showed mitochondrial red IMSRP fluorescence with an average ratio of 0.5 for roGFP. In treated cells, all cells with an increase in roGFP showed mitochondrial membrane permeabilization as evidence from diffused IMS-RP fluorescence. (C). U2OS cells stably expressing mt-roGFP were left untreated or treated with camptothecin (30 µM) and EGCG (50 µM) for 24 h. The cells were stained with annexin-V Alexa 647 to detect PS exposure to the plasma membrane as a measure of apoptosis. Control cells failed to show any annexin-V staining. In treated cells, there is a significant increase in annexin-V staining. (D). U2OS cells stably expressing mt-roGFP along with Smac-mCherry were treated with cisplatin (150 µM) and was subjected to fluorescent time-lapse imaging. The white arrowheads mark the cells’ initial surge in redox ratio concomitant with Smac-mCherry release. The yellow arrowheads indicate the drastic secondary increase in ratio subsequent to complete release of Smac-mCherry. (E). U2OS cells stably expressing mt-roGFP were either left untreated or pre-treated with MitoQ followed by drug treatment or drug alone as indicated for 24 h. Cells treated with MitoQ show lower redox ratio compared with corresponding drug alone treated. (F). Quantitative representation of the percentage of cell death in cells pre-treated with MitoQ followed by drug treatment or drug alone as indicated for 24 h.
Fig. 3(A). U2OS cells stably expressing mt-roGFP were grown on 96-well imaging plates as described. The automated imaging was carried out for roGFP ratio. The merged image of 405 nm and 488 nm signal and ratio images from representative wells are shown. The scatter plot shows ratio against granularity of 488 nm signal. (B). (i) U2OS cells expressing mt-roGFP were segmented (upper panel) based on 405 nm intensity threshold, incomplete mitochondrial segmentation is evident. (ii) U2OS (lower panel) cells expressing mt-roGFP with H2B-mcherry were segmented based on mcherry intensity signal and polygon band as described. Complete and proper segmentation is evident. (C). U2OS cells expressing mt-roGFP with H2B-mcherry were treated with resveratrol (200 µM) for 24 h. Representative ratio image and scatter plot obtained from high-throughput image is shown.
Fig. 4(A). U2OS cells expressing mt-roGFP with H2B-mcherry were segmented using Nikon NIS-elements software. (B). U2OS cells expressing Mito RO GFP were treated with resveratrol (200 µM), and real-time time-lapse imaging was carried out as described. Representative image at different time points is shown. (C). U2OS cells expressing mt-roGFP was stained with TMRM and treated with camptothecin (30 µM) for 24 h. The confocal imaging for ratio and TMRM was carried out as described. Representative ratio image, TMRM staining, and DIC images from indicated time points are shown. The lower panel shows the correlation plot of TMRM intensity with mt-roGFP ratio after 12 h of treatment. (D). U2OS cells expressing mt-roGFP was stained with TMRM and treated with staurosporine (2 µM) for 24 h. The confocal imaging for ratio and TMRM was carried out as described. Representative ratio image, TMRM image, and DIC images from indicated time points are shown. The lower panel shows the correlation plot of TMRM intensity with mt-roGFP ratio after 12 h of treatment. (E). U2OS cells expressing mt-roGFP was stained with TMRM and treated with camptothecin (30 µM) and for 24 h. The confocal imaging for ratio and TMRM was carried out as described. The TMRM release were plotted against roGFP ratio change.
Fig. 5(A) U2OS cells stably expressing mt-roGFP were treated with different anticancer agents as indicated for 24 h. Cells were stained with Alexa 647- Annexin-V followed by FACS analysis of roGFP ratio against Annexin-V. (B). U2OS cells stably expressing mt-roGFP treated with different anticancer agents as indicated for 24 h after staining with TMRM as described. FACS analysis of roGFP against TMRM fluorescence was carried out.